3 days popular7 days popular1 month popular3 months popular

2 knock-out punches delivered to glioblastoma cells by orphan receptor proteins

Two related proteins exert a lethal double whammy effect against cells when activated with a small molecule, say researchers at .

The scientists say when activated, one protein, called the short form, stops glioblastoma cells from replicating their DNA, and the other, called the long form, prevents cell division if the DNA has already been replicated, explains , PhD, assistant professor of oncology at . The study was posted online recently in the journal Cell Cycle.

Both proteins are produced by the (ERR?) gene. They are known as “orphan receptors” because they don’t bind to any substances naturally produced by the body. ERR? proteins are similar in shape to the receptor that binds the hormone estrogen — hence their name — but they do not bind estrogen and are not otherwise related. Both men and women have ERR? genes.

In this study, Riggins and her co-author, postdoctoral fellow Mary Heckler, PhD, examined glioblastoma cells in the laboratory for the presence of ERR? and found both long and short forms. To understand what these proteins were doing, they used a laboratory chemical, DY131, which had been designed to bind and activate these proteins.

To their surprise, the researchers discovered that DY131 exerted a strong, but distinct, effect on both the short and long forms of ERR?. The short form had been known to act as a tumor suppressor in prostate cancer, and a similar anti-cancer action was found by the researchers in glioblastoma. The study, however, is the first to find a function for the long form in cancer.

“While much work remains to understand the clinical potential of this finding, it may ultimately be possible to directly target the long and short forms of ERR? in combination with other therapies to improve outcomes in glioblastoma,” Riggins says.

Riggins, a member of the breast cancer program at Georgetown Lombardi, is now studying the behavior of the same proteins when activated by DY131 in triple negative breast cancer, for which there is no therapeutic target.

Source

The study was funded by a pilot grant from Partners in Research and the National Cancer Institute (R21CA191444 and T32CA009686).

Georgetown University Medical Center